Nintedanib Eignapharma

Nintedanib, the active ingredient in Nintedanib Eignapharma, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It is used to treat idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib is indicated for fibrotic lung disorders and selected oncologic settings, acting on pathways that drive fibroblast proliferation and tumor angiogenesis.

Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. Non‑small cell lung cancer (in combination therapy): contributes to inhibition of tumor growth and disease progression.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea - Nausea - Vomiting - Abdominal pain - Decreased appetite - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Severe hepatic injury or hepatitis - Major bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Gastrointestinal perforation - Severe infections - Pulmonary hypertension

When prescribing Nintedanib, clinicians should consider several safety measures.

Monitor liver function: perform baseline and periodic ALT/AST assessments. Assess bleeding risk: evaluate concomitant anticoagulant or antiplatelet therapy. Evaluate cardiovascular status: watch for hypertension or ischemic events. Avoid use in severe hepatic impairment: contraindicated in patients with Child‑Pugh C. Pregnancy and lactation: use only if potential benefit justifies risk; discuss with patient. Store at below 25°C: keep in the original container, protect from moisture and light.

Nintedanib can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - P‑gp inhibitors (e.g., verapamil): modestly increase plasma concentrations. - Diuretics: may exacerbate dehydration and renal impairment. - Antihypertensives: monitor blood pressure as nintedanib can cause hypertension.